Alnylam Pharmaceuticals
ALNY
#856
Rank
A$42.45 B
Marketcap
A$317.25
Share price
1.24%
Change (1 day)
-51.65%
Change (1 year)
Alnylam Pharmaceuticals Inc. is a biopharmaceutical company focused on the R&D and commercialization of RNA interference (RNAi) therapeutics for genetically defined diseases.

Earnings for Alnylam Pharmaceuticals (ALNY)

Earnings in 2026 (TTM): A$1.29 Billion

According to Alnylam Pharmaceuticals 's latest financial reports the company's current earnings are A$4.28 Billion. In 2025 the company made an earning of A$0.89 Billion, an increase over its 2024 earnings that were of -A$0.34 Billion. The earnings displayed on this page is the company's Pretax Income.

Earnings history for Alnylam Pharmaceuticals from 2003 to 2026

Annual earnings

Year Earnings Change
2026 (TTM) A$1.29 B43.5%
2025 A$0.89 B-369.48%
2024 -A$0.34 Billion-24.59%
2023 -A$0.45 Billion-67.84%
2022 -A$1.38 Billion36.93%
2021 -A$1.01 Billion-8.04%
2020 -A$1.1 Billion-15.66%
2019 -A$1.3 Billion12.23%
2018 -A$1.16 Billion62.91%
2017 -A$0.71 Billion17.78%
2016 -A$0.61 Billion43.44%
2015 -A$0.42 Billion60.69%
2014 -A$0.27 Billion98.2%
2013 -A$0.14 Billion
2011 -A$77.66 Million27.48%
2010 -A$60.92 Million-10.92%
2009 -A$68.39 Million95.77%
2008 -A$34.94 Million
2006 -A$55.96 Million-9.13%
2005 -A$61.59 Million34.74%
2004 -A$45.71 Million36.79%
2003 -A$33.42 Million

Earnings for similar companies or competitors

Company Earnings Earnings differencediff. Country
Novartis
NVS
A$22.35 B 1,714.95%๐Ÿ‡จ๐Ÿ‡ญ Switzerland
Sanofi
SNY
A$10.84 B 780.62%๐Ÿ‡ซ๐Ÿ‡ท France
Regeneron Pharmaceuticals
REGN
A$7.30 B 492.97%๐Ÿ‡บ๐Ÿ‡ธ USA
Sarepta Therapeutics
SRPT
A$34.65 M-97.19%๐Ÿ‡บ๐Ÿ‡ธ USA
Regulus Therapeutics
RGLS
-A$67.19 Million-105.45%๐Ÿ‡บ๐Ÿ‡ธ USA
OPKO Health
OPK
-A$0.33 Billion-126.33%๐Ÿ‡บ๐Ÿ‡ธ USA
Teva Pharmaceutical Industries
TEVA
A$3.21 B 161.13%๐Ÿ‡ฎ๐Ÿ‡ฑ Israel
Arrowhead Pharmaceuticals
ARWR
-A$0.23 Billion-118.38%๐Ÿ‡บ๐Ÿ‡ธ USA